Search results
BioLineRx reports positive pancreatic cancer trial results By Investing.com
Investing.com· 2 days ago(NASDAQ: BLRX), a biopharmaceutical company, announced encouraging results from the pilot phase of...
For most, pancreatic cancer is a deadly diagnosis. How one Fort Worth man beat the odds
Fort Worth Star-Telegram McClatchy via AOL· 6 days agoPancreatic cancer has one of the lowest five-year survival rates of any major tumor type,” said Dr....
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to...
Morningstar· 2 days agoFN Media Group News Commentary - The pancreatic cancer market encompasses the pharmaceutical and healthcare sectors dedicated to addressing the prevention ...
Aggressive cancers are killing people at younger ages | The Excerpt
USA Today· 6 days agoOn Sunday’s episode of The Excerpt podcast: Early-onset cancer is now considered a global health...
...Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American...
FOX 23 News Albany· 2 days agoThe CheMo4METPANC trial is evaluating the company's CXCR4 inhibitor motixafortide, the PD-1...
The quest to alter our ‘last toxic act’: Inside the rise of human composting
Los Angeles Times· 4 days agoIt was nearly dark outside when Blaire Van Valkenburgh strode through the woods, lanterns dangling...
Alligator Bioscience To Present Positive Phase 2 Mitazalimab Data in Pancreatic Cancer at 2024 ASCO...
Morningstar· 3 days agoOPTIMIZE-1 study results showed confirmed ORR of 40.4%, unconfirmed ORR of 50.9% and DCR of 79% in 57 evaluable patients with chemotherapy-naïve mPDACThe encouraging duration of response (median ...
29 Celebrities Who Have Had Breast Cancer
SheKnows via Yahoo News· 5 days agoFrom A-list celebrities to the people in our own lives, breast cancer can can truly happen to anyone — and the stats show it. After skin cancer, breast...
... in Combination with anti-PD-1 for First Line Recurrent and/or Metastatic Head and Neck Cancer to...
Yucaipa News Mirror· 2 days agoRakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell-targeting photoimmunotherapy based on its proprietary Alluminox™ platform, today announced ...
ASCO: Early peek at Merus' bispecific cancer data lives up to investors' expectations
FierceBiotech· 2 days agoAnalysts have hailed Merus’ latest data drop in head and neck cancer as meeting investors’...